In a significant stride for China's presence on the global stage of cell immunotherapy, Professor HUANG He from the Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU) has been at the forefront, showcasing remarkable advancements in CAR T-cell therapy. Recently, the contributions of his team were highlighted in February, during the 6th European CAR-T Conference held in Valencia, Spain, where he delivered insights into China's innovative strides in the field, particularly emphasizing novel CAR T-cell therapies for refractory/relapsed hematological malignancies.

Prof.HUANG's keynote speech “Novel CAR T-cell Therapy for R/R Hematological Malignancies” illuminated the significant progress made within China in cell immunotherapy, with a special focus on pioneering CAR-T therapies. These include remarkable contributions made by the center in innovative CAR-T approaches such as non-viral PD-1 targeted CAR-T, GPRC5D CAR-T for multiple myeloma, and CD7 CAR-T, among others. The team’s work not only charts the course for future developments in cell immunotherapy in China but also sets a global benchmark.

In addition to his presentation, Prof. HUANG represented China in a high-level discussion among top CAR-T experts from around the world, sharing China's achievements and experiences in CAR-T therapy. This engagement underscored the international interest in and the recognition of China's advancements in this cutting-edge field. His interactions highlighted the enthusiastic international response to China's success stories in CAR-T therapy, fostering dialogue on key aspects of CAR-T development and application.

Furthermore, Prof.HUANG also shared his insights with The Video Journal of Hematology and Hematological Oncology, focusing on the evolution and application of CAR T-cell therapies in China. These discussions not only amplified the international impact of China's work in cell immunotherapy but also underscored the innovative targets and clinical applications being explored in Chinese research.

China's foray into CAR-T therapysignifies a monumental leap in clinical application and research, positioning the country at the forefront of international cell immunotherapy. The work being done at FAHZU, in particular, has gained global attention for its innovative therapeutic targets, enhancements in therapy function, and the development of universal CAR-T therapies, showcasing the dynamic progress and potential of China's research in this field.

Professor HUANG's active engagement and recognition at an international level not only reflect the high regard for China's hematological research but also highlight the global influence of Chinese innovations in cell immunotherapy. This prominence paves the way for further high-quality collaborations and exchanges, accelerating scientific discoveries and technological advancements in the battle against hematological malignancies. Through dedication and innovation, China is poised to enhance healthcare outcomes and offer new hope to patients worldwide.

Source: The First Affiliated Hospital, Zhejiang University School of Medicine